Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

Verona Pharma in the NEWS
Yesterday, June 26, 2024, Verona Pharma plc (VRNA) announced that the US FDA has approved Ohtuvayre (ensifentrine) for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. The product . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.